BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Keymed Biosciences readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Keymed Biosciences's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05299424-3157@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gamgertamig (CM336): Phase 1/2 readout est. (NCT05299424)
DESCRIPTION:Gamgertamig (CM336)\, phase 1/2\, Multiple Myeloma.\nStudy: A S
 tudy of CM336 in Patients With Relapsed or Refractory Multiple Myeloma\nEs
 timated primary completion: December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05299424
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07106372-1335@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:stapokibart: Phase 3 readout est. (NCT07106372)
DESCRIPTION:stapokibart\, phase 3\, Atopic Dermatitis.\nStudy: A Study of S
 tapokibatrt in Children Subjects With Atopic Dermatitis\nEstimated primary
  completion: February 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/stapokibart#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07106372
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06830395-3258@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Lumrotatug: Phase 2 readout est. (NCT06830395)
DESCRIPTION:Lumrotatug\, phase 2.\nStudy: Study of CM313 in Subject With Ig
 A Nephropathy\nEstimated primary completion: March 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/lumrotatug#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06830395
URL:https://assetmemo.bio/drug/lumrotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011524-1337@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270721
DTEND;VALUE=DATE:20270722
SUMMARY:CM512: Phase 2 readout est. (NCT07011524)
DESCRIPTION:CM512\, phase 2\, Asthma.\nStudy: Study of CM512 Injection in S
 ubjects With Moderate-to-severe Asthma\nEstimated primary completion: 21 J
 uly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cm512#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07011524
URL:https://assetmemo.bio/drug/cm512#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181239-3157@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Gamgertamig (CM336): Phase 3 readout est. (NCT07181239)
DESCRIPTION:Gamgertamig (CM336)\, phase 3\, Multiple Myeloma.\nStudy: Study
  of CM336 in Relapsed or Refractory Multiple Myeloma Patients\nEstimated p
 rimary completion: September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/gamgertamig-cm336#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07181239
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07807826-1337@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:CM512: Phase 3 readout est. (NCT07807826)
DESCRIPTION:CM512\, phase 3.\nStudy: A Study of CM512 in Patients With Chro
 nic Rhinosinusitis With Nasal Polyposis (NEZHA-3)\nEstimated primary compl
 etion: November 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /cm512#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07807826
URL:https://assetmemo.bio/drug/cm512#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792019-3258@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:Lumrotatug: Phase 1/2 readout est. (NCT06792019)
DESCRIPTION:Lumrotatug\, phase 1/2.\nStudy: Study of CM313(SC) Injection in
  Subjects With Platelet Transfusion Refractoriness\nEstimated primary comp
 letion: 16 November 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/lumrotatug#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06792019
URL:https://assetmemo.bio/drug/lumrotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175493-3157@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271118
DTEND;VALUE=DATE:20271119
SUMMARY:Gamgertamig (CM336): Phase 1/2 readout est. (NCT07175493)
DESCRIPTION:Gamgertamig (CM336)\, phase 1/2.\nStudy: A Study of CM336 in Pa
 tients With Relapsed or Refractory Autoimmune Cytopenia\nEstimated primary
  completion: 18 November 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/gamgertamig-cm336#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07175493
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06791824-3258@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lumrotatug: Phase 1/2 readout est. (NCT06791824)
DESCRIPTION:Lumrotatug\, phase 1/2.\nStudy: Study of CM313(SC) Injection in
  Subjects With Relapsed/Refractory Aplastic Anemia\nEstimated primary comp
 letion: December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/lumrotatug#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06791824
URL:https://assetmemo.bio/drug/lumrotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230483-1337@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:CM512: Phase 2 readout est. (NCT07230483)
DESCRIPTION:CM512\, phase 2\, Atopic Dermatitis.\nStudy: A Long-term Safety
  and Efficacy Study Evaluating CM512 in Atopic Dermatitis.\nEstimated prim
 ary completion: December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/cm512#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07230483
URL:https://assetmemo.bio/drug/cm512#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06980142-1337@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280317
DTEND;VALUE=DATE:20280318
SUMMARY:CM512: Phase 2 readout est. (NCT06980142)
DESCRIPTION:CM512\, phase 2\, Chronic Obstructive Pulmonary Disease.\nStudy
 : A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive
  Pulmonary Disease\nEstimated primary completion: 17 March 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/cm512#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06980142
URL:https://assetmemo.bio/drug/cm512#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07519577-1337@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:CM512: Phase 2 readout est. (NCT07519577)
DESCRIPTION:CM512\, phase 2.\nStudy: A Study of CM512 in Patients With Chro
 nic Rhinosinusitis With Nasal Polyposis （NEZHA-2）\nEstimated primary c
 ompletion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/cm512#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07519577
URL:https://assetmemo.bio/drug/cm512#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890350-1337@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:CM512: Phase 2 readout est. (NCT07890350)
DESCRIPTION:CM512\, phase 2.\nStudy: Study of CM512 Injection in Patients W
 ith Perennial Allergic Rhinitis on Background Therapy\nEstimated primary c
 ompletion: June 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /cm512#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07890350
URL:https://assetmemo.bio/drug/cm512#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07910903-3157@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Gamgertamig (CM336): Phase 3 readout est. (NCT07910903)
DESCRIPTION:Gamgertamig (CM336)\, phase 3\, Multiple Myeloma.\nStudy: Study
  of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractor
 y Multiple Myeloma\nEstimated primary completion: May 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07910903
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06547333-1335@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20320429
DTEND;VALUE=DATE:20320430
SUMMARY:stapokibart: Phase 2/3 readout est. (NCT06547333)
DESCRIPTION:stapokibart\, phase 2/3\, Chronic Obstructive Pulmonary Disease
 .\nStudy: A Study of CM310 in Subjects With Moderate to Severe Chronic Obs
 tructive Pulmonary Disease\nEstimated primary completion: 29 April 2032. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/stapokibart#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06547333
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05761028-1335@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:stapokibart: Phase 2/3 readout est. (NCT05761028)
DESCRIPTION:stapokibart\, phase 2/3\, Asthma.\nStudy: A Study of CM310 in S
 ubjects With Moderate to Severe Asthma\nEstimated primary completion: May 
 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/stapokibart#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0576102
 8
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
